Can we genetically engineer safer and more effective immunotherapy reagents?
- 1 December 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 3 (6) , 495-500
- https://doi.org/10.1097/00130832-200312000-00012
Abstract
Progress in allergen-specific immunotherapy, the only causative form of allergy treatment, was limited by the lack of defined allergen molecules for vaccine formulation. Today the genetic informations for the most common allergens have been obtained. Here we review recombinant allergen-based technologies for the improvement of diagnosis and therapy of allergy. Numerous strategies, including the genetic engineering of allergens for reduction of allergenic activity, have been developed to improve allergen-specific immunotherapy. Genetically modified allergen derivatives with reduced allergenic activity, preserved T cell epitope repertoire and retained immunogenicity have been characterized in vitro and in vivo. Based on the review of the recently published data we argue that it is possible to genetically engineer safer and more effective immunotherapy reagents.Keywords
This publication has 53 references indexed in Scilit:
- Conversion of grass pollen allergen-specific human IgE into a protective IgG1 antibodyEuropean Journal of Immunology, 2002
- Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicityThe FASEB Journal, 2002
- Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatmentThe FASEB Journal, 2002
- Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapyEuropean Journal of Immunology, 2002
- Monovalent fusion proteins of immunoglobulin E mimotopes are safe for therapy of type I allergyThe FASEB Journal, 2001
- Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccinationThe FASEB Journal, 2001
- Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1The FASEB Journal, 2001
- Antibody Binding of Deletion Mutants of Asp f 2, the Major Aspergillus fumigatus AllergenBiochemical and Biophysical Research Communications, 2000
- Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998
- False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens☆☆☆★★★Journal of Allergy and Clinical Immunology, 1996